Details of the Drug Reposition

General Information of This Drug (ID: DMB5CKZ)

Drug Name
AEB1102   DMB5CKZ

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Arginase 1 deficiency DISAGUMY 5C50.A2 Phase 2 [1]
------------------------------------------------------------------------------------
1 Phase 1/2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Small-cell lung cancer DISK3LZD 2C25.Y Phase 1/2 [2]
------------------------------------------------------------------------------------
3 Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Solid tumour/cancer DISZR48F 2A00-2F9Z Phase 1 [2]
Myelodysplastic syndrome DISYHNUI 2A37 Phase 1 [2]
Acute myeloid leukaemia DIS0BM1I 2A60 Phase 1 [2]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT03378531) A Study of AEB1102 (Pegzilarginase) in Patients With Arginase I Deficiency (AEB1102). U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)